The Discounted Cash Flow (DCF) valuation of Chinook Therapeutics Inc (KDNY) is (99.55) USD. With the latest stock price at 40.39 USD, the upside of Chinook Therapeutics Inc based on DCF is -346.5%.
Based on the latest price of 40.39 USD and our DCF valuation, Chinook Therapeutics Inc (KDNY) is a sell. selling KDNY stocks now will result in a potential gain of 346.5%.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| WACC / Discount Rate | 5.8% - 7.1% | 6.4% |
| Long-term Growth Rate | 3.0% - 5.0% | 4.0% |
| Fair Price | (296.16) - (61.06) | (99.55) |
| Upside | -833.3% - -251.2% | -346.5% |